# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald suspends Overweight rating on Verona Pharma PLC ADR (NASDAQ:VRNA) and Maintains $100 price target
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, which e...
LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), ...
Verona Pharma (NASDAQ:VRNA) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.04 b...
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Verona Pharma (NASDAQ:VRNA) from Buy to Neutral and raises the...